Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment With USL-221 [estradiol] on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Postmenopausal Patients.

Next Previous
Trial Profile

Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment With USL-221 [estradiol] on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Postmenopausal Patients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Estradiol (Primary)
  • Indications Hot flashes; Menopausal syndrome
  • Focus Therapeutic Use
  • Sponsors Upsher-Smith

Most Recent Events

  • 30 Jun 2009 Results of a secondary analysis presented at the 57th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) according to an Upsher-Smith media release.
  • 17 Feb 2009 Results published in Menopause: Journal of the North American Menopause Society, according to a Upsher-Smith media release.
  • 25 Sep 2008 Results of additional analyses were presented at the North American Menopause Society's 19th Annual Meeting. These analyses investigated the effects of uterine status, age and body mass index on response to treatment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top